A real world extended access program to assess effect of sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis
Latest Information Update: 19 Oct 2020
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Expanded access; Therapeutic Use
- Sponsors Gilead Sciences
- 19 Oct 2020 New trial record
- 29 Aug 2020 Results (n=89) presented at The International Liver Congress 2020